AcelRx, Boston hospital to study DSUVIA opioid in patients undergoing spine surgery

Alan Condon -   Print  |

AcelRX Pharmaceuticals is partnering with Brigham and Women's Hospital in Boston to study the perioperative use of DSUVIA in the analgesic regimen for spine surgery.

Three insights:

1. DSUVIA, a synthetic opioid tablet, received FDA approval in 2018.

2. The study will explore if DSUVIA is linked with a decrease in pain intensity in the recovery room, opioid consumption and side effects, number of IV fentanyl boluses and hospitalization costs.

3. Richard Urman, MD, associate professor of anesthesia and co-director of the center for perioperative research at BWH and Boston-based Harvard Medical School is leading the study.

More articles on spine:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo's 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers